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Abstract: Recent advances in locoregional chemotherapy have opened the door to new approaches for
the clinical management of peritoneal carcinomatosis (PC) by facilitating the delivery of anti-neoplastic
agents directly to the tumor site, while mitigating adverse effects typically associated with systemic
administration. In particular, an innovative intra-abdominal chemotherapeutic approach, known
as Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC), was recently introduced to the
intraperitoneal (IP) therapy regimens as a palliative therapeutic option in patients with PC, presumably
providing a better drug distribution pattern together with deeper drug penetration into tumor nodules
within the peritoneal space. Furthermore, the progress of nanotechnology in the past few decades has
prompted the application of different nanomaterials in IP cancer therapy, offering new possibilities
in this field ranging from an extended retention time to sustained drug release in the peritoneal
cavity. This review highlights the progress, challenges, and opportunities in utilizing cancer
nanotherapeutics for locoregional drug delivery, with a special emphasis on the aerosolization
approach for intraperitoneal therapies.
Keywords: peritoneal carcinomatosis; PIPAC; nebulization; nanomedicine; localized chemotherapy;
intraperitoneal administration
1. Introduction
Cancer is recognized as a major public health problem in the world today and is the second leading
cause of death globally, exceeded only by cardiovascular diseases. Notwithstanding the fact that cancer
mortality rates are declining annually in both men and women owing to improved treatment and
organized screening, in 2019, 1,410,000 cancer deaths are projected to occur in the European Union
(EU) alone [1].
Cancer involves the formation of tumors by abnormal cell growth that can occur in any organ of
the body. The main cancer types are lung, prostate, colorectal, and stomach cancers for males, while
females most often suffer from breast, colorectal, lung, and cervical cancer. Furthermore, cancer cells
can spread and invade other tissues apart from the primary tumor site, leading to the formation of
metastases in other parts of the body.
To date, cancer treatment still often relies on the implementation of conventional cancer
chemotherapeutics that act by killing rapidly dividing cells. Chemotherapeutics like doxorubicin,
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taxanes (e.g., paclitaxel and docetaxel), or platinum-based agents (e.g., cisplatin, oxaliplatin, and
carboplatin) are frequently administered by intravenous delivery. Then, chemotherapeutics depend on
systemic transport to reach primary tumors or metastasis. The development of systemic chemotherapy
regimens greatly improved the survival rate of patients, although considerable obstacles still exist
that hinder the effective treatment of cancer. Systemic administration of chemotherapeutic agents
in the bloodstream is generally accompanied by a low therapeutic efficacy and severe toxicity in
healthy tissues ascribed to a short circulation half-life and off-target biodistribution, respectively [2]. In
addition, only a fraction of the administered dose ends up at the tumor site and maintaining adequate
drug levels within the tumors poses a significant challenge. Furthermore, the high compactness of
most solid tumors impedes the deep penetration of chemotherapeutic drugs into the central regions of
the tumor which, in turn, gives rise to only the partial eradication of cancer cells at the periphery of the
tumor spheroid and around blood vessels [3,4]. Importantly, heterogeneities within tumors, as well
as between patients referred to as intratumoral and intertumoral heterogeneity, respectively, present
additional challenges to the development of effective personalized cancer therapies [5].
The locoregional administration of chemotherapeutics has great potential for addressing the
drawbacks associated with systemic chemotherapy. Localized chemotherapy—defined as the
application of chemotherapeutics directly to the target tissue—has several merits, such as the superior
local drug concentration and reduced adverse effects on organs distant from the injection site [6,7].
Consequently, a reduced dosage can be applied for localized cancer therapy, together with the need for
less frequent drug administration when compared to the intravenous administration route.
Clearly, however, not all tumors are easily accessible for locoregional treatment and when they
are, the first treatment option remains the surgical removal of the tumor nodules, whenever possible.
One specific cancer type that might significantly benefit from locoregional therapy is peritoneal
carcinomatosis (PC), originating from primary cancers of organs confined to the peritoneal cavity such
as the ovary, prostate, and colon cancer. PC is characterized by the spread of numerous small tumor
nodules (metastasis) onto the peritoneal membrane and is difficult to eradicate as the large surface of
the peritoneal cavity (~2 m2) in conjunction with poor vascularization of the peritoneum restrain the
potential of systemic chemotherapy for reaching the intraperitoneal (IP) tumor nodules.
Around forty years ago, the first intracavitary chemotherapy strategies [8–10] were proposed
for the clinical management of PC, relying on IP instillation of liquid antineoplastic drugs using an
indwelling catheter after removing all macroscopic peritoneal metastases with cytoreductive surgery
(CRS) [11–13]. Thus far, a variety of IP chemotherapy (IPC) techniques have been established, which
are mostly classified according to the temperature or administration timing as follows: normothermic
IPC, hyperthermic IPC (HIPEC), early postoperative IPC, and delayed postoperative IPC [14,15]
(Figure 1C,D). The clinical benefit of combining surgical cytoreduction with fluid-based intraperitoneal
chemotherapy in the management of PC has been well-evidenced for decades, although this combined
treatment modality is associated with a considerable morbidity and a substantial proportion of
patients have demonstrated a locally unresectable cancer [16,17]. Furthermore, it is postulated that
the potential effectivity of IPC is restricted by well-documented pharmacological limitations, such
as a poor penetration of the drug into peritoneal nodules and an inhomogeneous drug distribution
throughout the abdominal cavity, resulting in an unsatisfying treatment outcome [18].
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Figure 1. Examples of intraperitoneal chemotherapy methods along with representative advantages and
disadvantages of each approach. (A) Schematic illustration and (B) surgical procedure of Pressurized
Intraperitoneal Aerosol Chemotherapy (PIPAC). (C) Schematic illustration and (D) surgical procedure
of Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Recently, the nebulization of chemotherapeutics has proven to be a well-suited and efficacious drug
delivery mode for the treatment of inoperable tumors and for the prevention of local tumor recurrence.
Aerosolized chemotherapy has depicted utility in several cancers, particularly lung malignancies
and peritoneal carcinom to is [19–23]. Interestingly, nebuliz ti n presents ttractiv possibilities for
localized cancer therapy throu h e suring homogenous drug distribution and optimal antitumor
effects, i combination with lower required doses [20–22,24,25]. This revie aims to shed light on
the progress, challenges, and opportunities in employing cancer therapeutics for locoregional drug
delivery, with a special emphasis on the nebulization approach for intraperitoneal therapies. Given the
recent advances in aerosol chemotherapy as a locoregional drug delivery approach, we first present
a new IP aerosolization strategy, referred to as Pressurized Intraperitoneal Aerosol Chemotherapy
(PIPAC), where we discuss the potential pharmacological advantages of PIPAC along with the technical
hurdles that need to be overcome to utilize this procedure in the clinical management of PC. Lastly, we
focus on the nanotechnology-based IP therapeutic modalities and particularly highlight the challenges
to the application of nanomedicine in IP nebulization therapy.
2. Aerosolized Drug Delivery of Chemotherapeutics
2.1. Principles and Proof of Concept o PIPAC
Over the past decades, aerosolization has established a foothold in cancer medicine, with a
strong emphasis placed on lung cancer therapy. In 1993, one of the first clinical studies regarding
the pulmonary administration of a chemotherapeutic (5-fluorouracil, 5-FU) was published, which
documented the implementation of nebulization chemotherapy by the administration of anticancer
agents through the inhalation of nebulized aerosols [22].
Lungs are regarded as appealing candidates for localized chemotherapy, in virtue of possessing
a large surface area for the rapid deposition of therapeutics, extensive vascularization with a weak
anatomical barrier, and a thin epithelial lining that does not limit the access to the possible lung cancer
metastatic sites [26,27]. Inhalation chemotherapy in lung cancer, which allows for local delivery of the
aerosolized chemotherapeutic agents to the site of disease, is non-invasive and could improve patient
compliance [23,28,29]. However, it should be noted that the existing drug clearance mechanisms
and bio-barriers in the respiratory airway systems, including mucus, ciliated cells, and resident
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macrophages, remain a challenge in the field of inhaled chemotherapy [30] and the development of
innovative aerosolizable drug delivery technologies has been found to be an indispensable requirement
in this field.
Besides locoregional delivery to the lungs, recent and exciting advances in nebulization
chemotherapy have paved the way for the clinical application of a new, minimally-invasive
intraperitoneal (IP) drug delivery technique, known as Pressurized Intraperitoneal Aerosol
Chemotherapy (PIPAC). PIPAC benefits from the aerosolization approach for the treatment of patients
diagnosed with end-stage cancers restricted to the peritoneal cavity.
The basic principles of the PIPAC procedure were developed and described in 2000 [31], while the
first application in humans was introduced a decade later, in November 2011 [32–35]. The concept of
PIPAC arose from the procedure performed during a diagnostic laparoscopy. Briefly, a constant 12-mm
Hg capnoperitoneum is created through the insuﬄation of CO2 at 37 ◦C and two balloon trocars are
introduced into the abdominal cavity (Figure 1A,B). A patented mono-component nozzle, the so-called
PIPAC Micropump (MIP®, Reger Medizintechnik, Rottweil, Germany), is connected to a high-pressure
injector with a high-pressure line and then inserted into the abdomen through one of the trocars. The
liquid cytotoxic drug is nebulized with the MIP® under a maximum pressure of 20 bars, generating
a polydisperse aerosol in the abdominal cavity, with a mean droplet size of 25 µm. The system is
maintained at a steady-state for 30 min at room temperature and the therapeutic capnoperitoneum is
then evacuated via a closed aerosol waste system.
There is substantial in vitro, in vivo, ex vivo, and clinical evidence that PIPAC offers superior
pharmacological advantages over the conventional intraperitoneal lavage [20,21,36] (Table 1). It has
been reported that the chemo-aerosol, formed during the PIPAC procedure, is assumed to behave in
a “gas-like” manner, and as a consequence, it could guarantee a homogenous distribution pattern
of cytotoxic substances within the entire intraperitoneal space, which in turn enhances the area of
peritoneal surface covered by the drug [20,21,37]. Furthermore, the artificial pressure gradient in the
shape of a 12 mm Hg capnoperitoneum generated during PIPAC is assumed to counteract the elevated
interstitial fluid pressure in tumor nodules, resulting in a superior drug penetration depth in peritoneal
nodules in comparison with liquid IP chemotherapy [21,36]. Prior experimental studies have indeed
confirmed that the increase in intraperitoneal pressure plays an important role in the absorption of
fluid from the peritoneal cavity and seems to enhance the in-tissue drug influx upon intraperitoneal
administration [38,39]. It has been shown by Solass and coworkers [20] that the penetration depth of
chemotherapeutics into peritoneal nodules and tissue was 500–600µm accompanied by high tissue drug
concentrations (0.03–4.1 µmol/g), which is considerably higher than noted for peritoneal lavage with a
liquid solution [39]. As such, PIPAC was able to introduce superior intratumoral drug concentrations
with only 10% of the usual dose applied in HIPEC, leading to the regression of peritoneal nodules
with limited hepatic and renal cytotoxicity. Furthermore, additional advantages are the possibility of
performing PIPAC sequentially or in addition to traditional systemic chemotherapy, as the repeatability
of the procedure can contribute to an enhanced treatment response and improved quality of life in
patients [20,40,41].
While the results that have been obtained up to now are encouraging, there remain several obstacles
to be overcome. Recently, published data collected from ex vivo and post-mortem animal investigations
demonstrated a non-uniform spatial drug distribution pattern within the entire abdominal cavity
during the PIPAC procedure. Granulometric characterization of the aerosol delivered by the MIP®
showed that 97.5 vol% of aerosol droplets are between 3–200 µm, which do not possess the suitable
physical properties to provide a homogenous drug distribution [42–44]. Hence, such droplets are
primarily deposited beneath the MIP® nozzle on the peritoneum by gravitational settling and inertial
impaction, creating extensive local aerosol “hot-spots”, rather than a homogenous distribution [42,45].
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Table 1. Examples of preclinical and clinical studies on the efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC).
Active Pharmaceutical Compounds Type of PIPAC Experimental Model/ExVivo, In Vivo, Clinical Trial Cancer Type Outcome Reference
1. Tracers and chemotherapeutics
Doxorubicin PIPAC Pig/ex vivo Fresh tissue samples of swineperitoneum
The study evidenced a heterogeneous drug distribution pattern of ex
vivo PIPAC, indicating a significantly higher penetration depth of the
drug in tissues directly exposed to the aerosol jet in comparison with the
ones placed on the side wall and the top of the box.
[43]
Doxorubicin PIPAC Pig/ex vivo Fresh postmortem swineperitoneum
Ex vivo data suggested that a higher drug dose and a closer positioning
of the Micropump towards the tissue samples could assist in a superior
drug penetration. Nevertheless, an increase in internal pressure did not
significantly change the penetration depth of doxorubicin. Furthermore,
changing the drug concentration and position of the nozzle, as well as
increasing the pressure, cannot noticeably give rise to a more
homogenous drug distribution pattern.
[46]
Methylene blue PIPAC Pig/in vivo Healthy animal
Significant improvement in both the biodistribution and penetration of
the test substance in the peritoneal cavity in a large animal model
compared to peritoneal lavage.
[21]
Methylene blue PIPAC Pig/in vivo Healthy animal
First description and development of basic principles of the PIPAC
procedure in vivo. This study showed that all exposed peritoneal
surfaces were stained by the methylene blue, indicating the partial
distribution of this active substance within the peritoneal cavity.
[31]
99mTc-Pertechnetate (isotopes of the radioactive
element technetium)
PIPAC Pig/in vivo Healthy animal
Using scintigraphic peritoneography, this study revealed the
inhomogenous intra-abdominal distribution pattern of aerosol during
the PIPAC procedure in a postmortem swine model.
[45]
Tracer substances (toluidine blue and DT01) ePIPAC Pig/in vivo Healthy animal
Obtained data showed that electrostatic precipitation of aerosolized
substances was technically feasible in all electrostatic PIPAC (ePIPAC)
animals. Generally, ePIPAC affords homogenous staining of peritoneal
surfaces and enhanced tissue uptake of tracers (up to tenfold) compared
to PIPAC.
[37]
99mTc-Pertechnetate/Doxorubicin/Methylene
blue
HINAT Pig/in vivo Healthy animal
Hyperthermic intracavitary nanoaerosol therapy (HINAT) was
introduced as an enhanced approach of PIPAC, generating hyperthermic
unipolar-charged nanosized aerosols which can in turn provide a more
uniform drug deposition throughout the peritoneal cavity along with
significantly deeper drug penetration.
[47]
Indocyanine green/Cisplatin H-PAC Pig/in vivo Healthy animal
In this study, a constant hyperthermic capnoperitoneum was created
using a heating apparatus. The feasibility and safety of hyperthermic
PIPAC (H-PAC) were shown in the porcine survival model.
[48]
Doxorubicin PIPAC Pig/in vivo Healthy animal
Aerosolized drugs can reach all areas within the peritoneal cavity,
although the highest penetration depth was observed in the peritoneal
surfaces around the Micropump.
[44]
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Table 1. Cont.
Active Pharmaceutical Compounds Type of PIPAC Experimental Model/ExVivo, In Vivo, Clinical Trial Cancer Type Outcome Reference
Doxorubicin + Cisplatin PIPAC Human/clinical trial
Advanced PC from gastric,
appendiceal, and ovarian
origin
Superior antitumor activity with a high local concentration and low
systemic toxicity. Regression of peritoneal carcinomatosis (PC) in
chemo-resistant tumors was observed using 10% of an usual systemic
dose.
[20]
Doxorubicin + Cisplatin PIPAC Human/clinical trial
Recurrent, platinum-resistant
ovarian, fallopian, or
peritoneal cancer with
peritoneal carcinomatosis
Safety and activity of PIPAC were assessed in patients. This approach
resulted in an objective tumor response and histological tumor
regression along with acceptable local and systemic toxicity. In general,
62% of patients in this trial achieved the clinical benefit.
[32]
Doxorubicin + Cisplatin PIPAC Human/clinical trial Gastric peritoneal metastasis PIPAC procedure was safe and induced an objective tumor response in50% of selected patients. [33]
Oxaliplatin PIPAC Human/clinical trial Colorectal peritonealmetastasis
This retrospective analysis revealed that repeated PIPAC can induce
considerable pathological responses in pretreated colorectal peritoneal
metastases while causing less local toxicity.
[34]
Oxaliplatin/Doxorubicin + Cisplatin PIPAC Human/clinical trial Peritoneal carcinomatosis
Safety and feasibility of PIPAC associated with systemic chemotherapy
were explored. Preliminary data showed that this combination therapy
did not lead to significant renal and hepatic toxicity. This combined
treatment may be beneficial for patients with extraperitoneal disease or
those at a high risk of disease development.
[35]
Doxorubicin + Cisplatin PIPAC Human/clinical trial Peritoneal carcinomatosis
A retrospective cohort study assessed the objective tumor response in a
pretreated population of women with peritoneal carcinomatosis. Results
showed that PIPAC can preserve the quality of life; however, appropriate
patient selection in terms of performance status and the number of
previous surgeries should be take into consideration.
[41]
Doxorubicin + Cisplatin ePIPAC Human/clinical trial
Peritoneal metastasis of
hepatobiliary-pancreatic
origin
These preliminary results in human patients suggested that ePIPAC is
well-tolerated and technically feasible and can induce the regression of
biologically aggressive tumors.
[49]
Doxorubicin + Cisplatin PIPAC Human/clinical trial Recurrent, platinum-resistantovarian cancer
A preliminary clinical report on the activity of PIPAC provided evidence
that PIPAC is well-tolerated in most patients and achieved an objective
tumor response in 6/8 cases.
[50]
Doxorubicin + Cisplatin PIPAC Human/clinical trial Peritoneal metastasis frompancreatic cancer
This case study reports on the activity of PIPAC through the induction of
histologic regression in pretreated patients with systemic chemotherapy. [51]
2. Biomolecules and Nanoparticles
Dbait (noncoding DNA fragments) coupled to
cholesterol molecule and Cy5 PIPAC Human/ex vivo
Human sample of peritoneal
carcinomatosis from an
endometrial adenocarcinoma
The fluorescence signal was detected in the tumor nodules up to 1 mm in
depth following aerosolization. On the contrary, no uptake was
observed in the lavage sample.
[36]
Lipofectamin RNAiMAX/siRNA complexes PIPAC Human/ in vitro Luciferase expressing ovariancancer cell line (Luc SKOV3)
This study revealed the pronounced in vitro stability of complexes in
ascites, as well as the noticeable transfection efficiency upon
nebulization.
[52]
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Table 1. Cont.
Active Pharmaceutical Compounds Type of PIPAC Experimental Model/ExVivo, In Vivo, Clinical Trial Cancer Type Outcome Reference
messengerMax/ Luc mRNA complexes PIPAC Rat/ in vivo Healthy animal
First study demonstrating the feasibility of high-pressure nebulization of
mRNA complexes to the peritoneal cavity of rats, affording a more
homogenous distribution of luciferase mRNA expression in the entire
peritoneal cavity compared to intraperitoneal injection.
[53]
Abraxane (albumin-bound paclitaxel) (FDA
approved) PIPAC Human/clinical trial
Unresectable peritoneal
metastasis from upper
gastrointestinal, ovarian, or
breast malignancies
Outcome to be determined. [54]
3. Nanoformulations potentially suitable for future implementation in PIPAC
Nanotax® (nanoparticle formulation of
paclitaxel)
IP
administration Human/clinical trial Peritoneal malignacies
Compared to IV-administered paclitaxel, intraperitoneal (IP)
administration of Nanotax®gives rise to higher paclitaxel (PTX)
concentrations in the peritoneal cavity for a prolonged period of time,
along with minimal sytemic exposure and a reduced toxicity.
[55]
1. Nano-taxol (liposomal Paclitaxel)
2. Nano-platin (polymeric micelle cisplatin)
3. Nano-topotecan (polymeric micelle topotecan)
4. Doxil (pegylated liposomal Doxorubicin)
(FDA approved)
IP
administration Mouse/in vivo
Peritoneal metastasis of
human ovarian cancer cell
line (ES-2-luc)
This study indicated that systemic delivery of all tested nanomedicines
failed to present a superior therapeutic efficacy compared with each free
drug counterpart. In addition, IP delivery of these nanotherapeutics
demonstrated a better antitumor activity only for Nano-taxol and
Nano-topotecan when compared to corresponding free drugs. It is
assumed that the structure of Abraxane and Doxil is considerably stable
to release the encapsulated drug in the peritoneal cavity for the effective
treatment of PC.
[56]
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These findings are consistent with the observations obtained by other studies. Khosrawipour et
al., for example, reported a remarkable variation in penetration depth between different regions of the
abdominal cavity [44,46]. The highest uptake of the aerosolized cytotoxic agent into tumor nodules
was observed in the opposite side and vicinity of the MIP® nozzle with an in-tissue penetration depth
of >311 µm compared to tissue samples located at more distant sites from the aerosol jet created
by the MIP®. Therefore, the proximity of peritoneal tissue to the MIP® could be regarded as a
crucial parameter affecting the uptake of chemotherapeutics into peritoneal nodules during the PIPAC
procedure [43–45].
Recently, new types of PIPAC methods have been developed to address the hurdles associated
with this chemotherapy approach. For example, Jung Do et al. previously evaluated the feasibility and
safety of combining the benefits of PIPAC technology with hyperthermia in a porcine model, known
as hyperthermic PIPAC (H-PAC) [48]. Göhler et al. recently established an improved hyperthermic
version of PIPAC in a swine model for the treatment of end-stage PC, termed hyperthermic intracavitary
nanoaerosol therapy (HINAT) [47]. Here, the application of a nanoaerosol resulted in a more uniform
drug distribution pattern and deeper in-tissue drug penetration in an intracavitary hyperthermic
condition [47]. Finally, electrostatic PIPAC (ePIPAC) was developed, in which the electrostatic
precipitation of the therapeutic aerosol was shown to improve the distribution pattern and tissue uptake
of neoplastic agents in the peritoneal cavity, when compared to PIPAC alone [37,49]. Nevertheless,
beyond technical innovations in the optimization of intra-abdominal aerosol therapy, PIPAC is still
in its infancy and numerous challenges are expected. Furthermore, as PIPAC is only performed in
patients who are no longer eligible for CRS and HIPEC, it should be considered as palliative care and
CRS and HIPEC remain the standard of care for patients diagnosed in more early stages of the disease,
despite their more invasive character (Figure 1C,D).
2.2. Clinical Studies on the Effectiveness of PIPAC
The PIPAC approach has offered new hope for the treatment of various peritoneal surface
malignances (e.g., ovarian, gastric, and colorectal carcinomatosis), employing different anticancer
substances such as cisplatin, oxaliplatin, and doxorubicin (Table 1). Given the success of PIPAC in
preclinical studies, including in vivo [21] and ex vivo [36] models, Solass and co-workers attempted to
investigate the first application of this treatment modality in human patients using cisplatin (7.5 mg/m2
body surface area) combined with doxorubicin (1.5 mg/m2). Despite an overall dose reduction, they
documented significant antitumor activity by demonstrating high concentrations of doxorubicin in
peritoneal nodules and tumor regression, even in platinum-resistant tumors with diminished renal
and hepatic toxicity [20]. Another preliminary clinical study details the procedure and outcome of
PIPAC with cisplatin and doxorubicin in 21 women with recurrent platinum-resistant ovarian cancer.
In 3/21 of the selected patients, PIPAC was attempted; however, it could not be carried out owing to
abdominal adhesions precluding laparoscopy required for this therapy. Therefore, further analyses
were limited to 18 patients which underwent at least one PIPAC. Thirty-four PIPAC procedures were
performed in these 18 patients in total, and in eight instances were combined with cytoreductive
surgery. This investigation provided the clinical evidence that PIPAC was well-tolerated in most
patients when applied without concomitant CRS and achieved an objective tumor response in 6/8 cases,
with complete remission, partial remission, and stable disease observed in one, two, and three patients,
respectively. A cumulative survival rate of 62% was noted 400 days after the beginning of treatment.
This suggested that PIPAC may be considered as a palliative therapy option in women suffering from
recurrent ovarian cancer, although further assessment in prospective clinical trials is needed [50].
Approximately one year later, the same group were included in a report on a phase 2 clinical
study concerning the efficacy of PIPAC administered with cisplatin and doxorubicin in patients with
recurrent, platinum-resistant ovarian, fallopian, or peritoneal cancer with peritoneal carcinomatosis.
The authors concluded that PIPAC results in an objective tumor response, the induction of histological
tumor regression coupled with an acceptable local and systemic toxicity, and the achievement of a
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clinical benefit rate of 62%. It was, however, envisaged that PIPAC still needs to be further examined
in comparative clinical trials and other chemotherapy compounds as alternative combinations of
cytotoxic agents may be valuable options for testing via the PIPAC approach [32].
Likewise, of note is a retrospective analysis, which was performed for the first time with the
aim of exploring the efficacy of PIPAC with oxaliplatin (92 mg/m2) in recurrent, pretreated colorectal
peritoneal metastasis. It was shown that PIPAC is capable of inducing an impressive response rate
and objective tumor regression in 12 out of 14 patients (86%) in a salvage situation. The procedure
was remarkably well-tolerated, with a limited local toxicity and indicated mean survival rate of
17.5 months after the first PIPAC application. It was suggested that the obtained results might provide
the rationale for prospective, comparative clinical studies investigating the potential of PIPAC as a
palliative therapy in patients with colorectal peritoneal metastasis who are not eligible for CRS and
HIPEC [34]. Similarly, in an additional study by Nadiradze et al., PIPAC was conducted with low-dose
cisplatin and doxorubicin, for the first time, in chemotherapy-resistant gastric peritoneal metastasis.
The study documented an objective tumor response in half of the patients (12/24), including complete
histological regression in six patients and a low incidence of severe adverse events. The obtained results
were in accordance with previous observations reported in ovarian [32,50] and colorectal cancer [34]
indicating encouraging survival data, although, as an exception, gastric cancer patients with malignant
pleural effusion did not benefit from the treatment regimen. Therefore, it was proposed that the data
should not be extrapolated to all patients with gastric peritoneal metastasis and additional research is
needed in this area [33].
More recently, a case study by Graversen and co-workers focused on the therapy of pretreated
peritoneal metastasis from a pancreatic origin through the application of PIPAC with low-dose cisplatin
and doxorubicin. In this pilot study, the induction of histological regression and overall survival
benefit suggested the activity and feasibility of PIPAC in these patients, although a larger study is
required for validation [51]. In addition to previous investigations, it has recently been revealed by a
retrospective cohort study that repetitive PIPAC procedures are feasible in the majority of patients
with refractory carcinomatosis of various origins with a reduced incidence of intraoperative and
postoperative complications, prompting the design of prospective analyses to monitor the oncological
efficacy of this therapeutic strategy [57]. To systematically analyze the mechanism, pharmacokinetics,
the safety and clinical efficacy of PIPAC, the available experimental and clinical evidence for this
IP chemotherapy strategy with a special emphasis on ovarian cancer have been summarized in a
recent review article [58]. In short, based on experimental studies, retrospective cohort studies, and
clinical phase I and II trials reporting >3500 procedures in >1500 patients with PC of various primary
malignancies, it is suggested that the management of PC with PIPAC is feasible and safe without
systemic toxicity. Additionally, PIPAC maintains and/or improves the quality of life in patients with PC
and recurrent cancers. Despite the clinical trial success in general, it is worth noting that further studies
will help to elucidate the true potential of the PIPAC approach for the widespread implementation
in a clinical setting. Furthermore, it is imperatively recommended that the efficacy of PIPAC in
clinical practice should be compared to other treatment modalities (e.g. CRS, HIPEC, and systemic
chemotherapy) in randomized phase III trials, as these studies are currently lacking.
3. Nanotherapeutics for Locoregional Cancer Therapy
3.1. Potential Benefits of Nanoparticulate Drug Delivery
The intrinsic limitations of conventional cancer therapeutics have ignited the growing interest
in applying nanotherapies to cancer, substantially attributed to their appealing hallmarks for drug
delivery, diagnosis, and imaging [59–61].
The fundamentals behind utilizing nanoscale delivery vehicles for cancer therapy stem from the
fact that they afford extended circulation, reduced toxicity, controlled release, and enhanced drug
protection compared to their free antineoplastic counterparts. Furthermore, it is widely believed that
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cancer nanotherapeutics can be further functionalized with targeting ligands to actively localize them
at the tumor site, leading to improved therapeutic efficacy and reductions in systemic side effects
by avoiding the delivery of cytotoxic drugs to nontumor cells [62]. Despite the enormous progress
in the field of cancer nanomedicine, only a few nanotechnology-based therapeutic products, such
as liposomes, albumin nanoparticles, and polymeric micelles, have been clinically approved by the
Food and Drug Administration (FDA) for anticancer therapies so far, although more are in clinical
trials [63]. Clearly, challenges lie ahead regarding chemistry, manufacturing, and commercialization
before the clinical translation of a nanoparticle’s efficacy from preclinical animal models to humans
can be made [64].
Over the last few decades, nanotechnology has also been considered for local drug delivery
strategies. Notably, nanoparticles have become attractive candidates for IP drug delivery by virtue of
their tunable physicochemical features (for example, their size, charge, shape and surface chemistries,
and bioadhesive properties, among others), which facilitate bypassing the body clearance systems and
the release of therapeutic payloads to the tumor site [19,65]. In addition, IP-administered nanovehicles
not only have the ability to potentially lengthen the exposure of tumor nodules to chemotherapeutics,
but also slow down the absorption to the systemic circulation, thus lowering systemic adverse
effects [6,11,66–68]. Furthermore, nanoparticles (NPs) can be decorated with targeting ligands, which
could largely assist in tumor accumulation, retention, and the cellular uptake of antineoplastic agents,
while abrogating off-target effects [69–73]. The implementation of nanotherapeutics for localized
cancer chemotherapy is largely guided by the desire to maximize the therapeutic concentrations and
bioavailability of drugs nearby cancerous tissues over a longer period of time. We have previously
reviewed the challenges in using nanomedicines for the treatment of peritoneal carcinomatosis [19],
where nanoparticles are introduced in the peritoneal cavity through the injection of a solution or
imbedded in controlled release hydrogel formulations [74–76]. In the following section, we will discuss
the rationale behind using therapeutic nanocomplexes for intraperitoneal nebulization and provide an
overview of existing challenges and future perspectives for the use of PIPAC for the local application
of nanomedicine.
3.2. Challenges and Opportunities for the Nebulization of Nanomedicine in the Peritoneal Cavity
Provided that cancer nanomedicine in the IP drug delivery area continuously advances, a new
opportunity may be created for exploiting the potential of nanoparticulate systems combined with the
PIPAC procedure. It should be noted, however, that our current understanding of how nanoparticle
systems behave when intraperitoneally nebulized through PIPAC is insufficient due to the very few
research studies that have been devoted to exploring this subject. Herein, one of the first challenges
is the colloidal stability of nanoparticle formulations when exposed to forces generated during IP
nebulization (Figure 2A). Indeed, the ideal nanoscale systems should have the ability to be efficiently
transferred into aerosols, but on the other hand, should endure a high aerosolization pressure to hinder
any dramatic alterations in the structure, composition, and functionality. Problems which might occur
under the influence of nebulization are nanoparticle aggregation, premature payload release, and the
loss of targeting capability, which are all expected to result in limited therapeutic activity. Furthermore,
in the case of hyperthermic PIPAC procedures, the chemical composition of NPs (in particular for
heat-sensitive and lipid-based nanomaterials) should withstand the high aerosol temperature (41–43 ◦C)
to prevent changes in nanoparticle formulations composed of low-melting-point materials.
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part from the nanoparticle, t e cargo it is carryi g should also be able to withstand the high
pressure during nebulization. For chemotherapeutics like doxorubicin, cisplatin, or paclit x l, t is
is ost likely less of an issue, given their low molecular weight and simple chemical structur .
Macromolecules like proteins, antibodies, and nucleic acids, however, might be more vulnerable to
structural alteratio s during nebulizatio as subtle changes in the 3D structure and folding of these
molecules ca already have a consequence n their biological activity. In a recent in vitro study,
however, Minn ert et al. demonstrated that nebulization is an appealing approach that can be used to
distribute Lipofecta i RNAiMAX/siRNA complexes in the peritoneal cavity, which maint in their
transfection effici cy upon aerosolizatio [52]. Furthermore, we have recently demonstrat d that
high-pr ssure nebulizati n of messenge Max/mRNA complexes to the perito eal cavity of adult
athymic nude rats is feasible, le ding to a homogenous distribution of luciferase mRNA expression in
the peritoneal cavity. Additionally, when compared to a IP injection, the aerosolization approach
see ed to result in a more uniform mRNA expr ssion which covered a larger surface are of the
peritoneum [53]. Therefore, these first in vivo results demonstrate that nucleic acids seemed to survive
the high pressure that was applied during the nebulization procedure. Neverth less, further in vivo
validation is indispensable to provide more insights into th halleng s f ced during the combined
application f nanotechnology-based drug delivery systems and the IP aerosolizati n strategy.
Another formulation that might be useful f r IP nebulization is Abraxane, n FDA-approved
nano article formulation of paclit x l (PTX), consisting of 4–14 nm PTX-albumin aggregates that
form an albumin-PTX nanoparticle of roughly 130 nm in diameter [77]. The strengths of Abraxane
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have been demonstrated through the activity in metastatic breast, pancreatic, and non-small cell
lung cancers. It is also noteworthy that recent preclinical and clinical studies have focused on the IP
administration of Abraxane for the treatment of platinum-resistant PC due to the superior antitumor
activity, favorable toxicity profile, and better overall response and survival compared with conventional
IV administration [78–81]. In this regard, pressurized IP aerosol administration of Abraxane has been
proposed by a recent phase I clinical study in patients with unresectable peritoneal metastasis from
upper gastrointestinal, ovarian, or breast malignancies, aiming to determine the maximum tolerated
dose (MTD) of Abraxane for prospective randomized phase II clinical trials of PIPAC therapy [54]. To
the best of our knowledge, this is the first in vivo study in humans trying to elucidate the feasibility
and added value of using PIPAC for the administration of a nanoparticle formulation, yet the outcome
still has to be determined. Apart from Abraxane, no other FDA-approved nanomedicines have
been evaluated for the treatment of peritoneal metastasis so far. There are about 50 FDA-approved
nanomedicines which are categorized as liposomal formulations, polymeric formulations, nanocrystals,
or drug conjugates [64,65,82,83]. Only a few of them are useful for the treatment of cancer (e.g.,
Doxil), but none of them have been specifically approved for intraperitoneal application. There are
nanomedicines currently being evaluated in preclinical and clinical studies for IP cancer therapies
(e.g., Nanotax and Nano-platin), which could have future potential for IP application through PIPAC
(Table 1). The use of a liposomal nanoformulation of cisplatin (e.g., Lipoplatin), however, is less likely
to be successful as encapsulated cisplatin showed a decreased efficacy when compared to the free
drug [84].
Nevertheless, it should be noted that the particular challenges that occur upon the IP injection of
nanomedicines will most likely remain after the nebulization of NPs in the peritoneal cavity. Indeed,
on the first contact of nebulized nanotherapeutics with the biological environment of the peritoneal
cavity, deposited particles are exposed to several potential bio-barriers. Importantly, aerosolized NPs
can come into contact with ascites fluid, which accumulates in the peritoneal cavity at an advanced
stage of PC. Considering the formation of even a limited amount of ascites fluid in patients with
peritoneal metastasis, who are eligible for the PIPAC procedure, it will be crucial to identify the
therapeutic efficacy of nebulized nanotechnology-based drug delivery carriers in ascites fluid in the
relevant in vitro settings before in vivo testing is pursued. In this regard, we have established an
advanced microscopy technique which has afforded us the unique possibility to explore the colloidal
stability of nanotechnology-based platforms in undiluted biofluids (e.g., ascites, blood, serum, and
plasma), which are also likely to be applicable for tracing the biological behavior of NPs following
in vivo administration [85]. By means of the fluorescent single particle tracking (f-SPT) method, we
are able to determine whether or not NPs remain colloidally stable (e.g., do not aggregate) and if the
premature release of cargo does not occur (Figure 2B). Indeed, biofluids such as ascites fluid have a
high protein content of which the negatively charged albumin might compete with the binding of
negatively charged cargo such as nucleic acids to the nanoparticles. Using SPT, we recently reported
that liposome-siRNA nanocomplexes were colloidally stable in the presence of ascites fluid obtained
from patients with PC, although their cellular uptake and ability to silence the target genes in the
SKOV3 cell line were substantially diminished [86].
Furthermore, when nanomedicines encounter biological fluids, different biomolecules (typically
proteins) present in these biofluids can be adsorbed by the nanoparticles, thereby immediately covering
their surface. This gives rise to the formation of a “protein corona”, which can alter the physicochemical
characteristics of NPs (for example, size, stability, and surface properties) and, more importantly,
dictates the biological responses that nanoparticles elicit, such as their cellular uptake, biodistribution,
and toxicity [87–92]. Additionally, it has become increasingly clear that the presence of this protein
corona can trigger recognition and phagocytosis of the nanoparticles by resident macrophages of the
mononuclear phagocyte system (MPS), located in filtering organs (i.e., the liver and spleen) (Figure 2C).
There exists empirical evidence suggesting that the size of IP-administered delivery vehicles can
largely control their peritoneal retention, in view of the fact that the majority of nano-sized drug
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delivery systems are rapidly cleared from the peritoneum and trafficked to the spleen and liver, where
they are exposed to macrophage clearance. Conversely, microparticles have revealed a prolonged
residence time in the peritoneal cavity, although the high incidence of peritoneal adhesions induced by
microparticles over a longer period of time may rule out their therapeutic application for long-term IP
therapy [93].
Besides macrophage clearance, a growing emphasis has been placed on the role of the lymphatic
system as a major factor in peritoneal clearance, which is to a great extent related to the micron-sized
diameter of lymphatic duct openings (in a murine model), hence particle size criteria come into play
once again (Figure 2D). It has been documented that small nano-sized formulations (less than 500 nm)
are readily drained through the lymphatic ducts and easily pass the lymph nodes to reach the system
circulation, whereas in the case of larger delivery vehicles, if their size approaches the size of lymphatic
duct openings, drainage via the lymphatic system is limited and they are mostly entrapped in the
lymph nodes instead [81,94–97].
In addition to particle size, the shape of therapeutic nanoparticles may be an important determinant
of IP therapy. Compared to their spherical counterparts, elongated nanostructures (for instance,
nanoworms and nanorods) with adequate geometric dimensions are thought to hamper the macrophage
clearance, as well as lymphatic drainage, thereby extending the residence time in the peritoneal
cavity [98–102]. It is also assumed that the high aspect ratio of non-spherical carriers may allow more
efficient deposition and superior coverage of the peritoneal surface following IP nebulization. Likewise,
the surface modification (e.g., Polyethylene Glycol (PEG) grafting) and charge (i.e., positive charge)
of a delivery vehicle also seem to be key to enhancing the peritoneal retention, by circumventing
phagocytosis by macrophages [103–105].
Finally, the penetration of nebulized nanotherapeutics to the peritoneal nodules poses an
additional challenge to IP drug delivery. The tumor microenvironment is characterized by a dense
extracellular matrix composed of collagen fibers and several different proteins [3,13]. Furthermore,
the elevated interstitial fluid pressure (IFP) caused by vascular hyperpermeability and the lack of
functional lymphatic vessels inside the tumor tissue, contribute to the poor penetration of NPs into
the tumor [3,13,106–108]. It is widely supposed that the high intra-abdominal pressure created during
PIPAC counteracts the interstitial hypertension in tumor nodules, providing a deeper in-tissue drug
penetration and superior antitumor efficacy for chemotherapeutics (Figure 2E). However, whether
or not PIPAC can also enhance the tumor penetration of nanoparticles remains unclear. One can
imagine, however, that the acceleration of nanoparticles during the nebulization procedure might help
to ‘shoot’ them deeper into tissue layers. Therefore, exploring the impact of the NP physicochemical
properties (e.g., size, charge, surface features, and geometry) on tumor penetration [101,102,109–114],
will be crucial to exploiting the potential of nanomedicine administration with the PIPAC approach.
Interestingly, the balloon trocars used in the PIPAC procedure allow the application of laser light into
the peritoneal cavity. This opens up the avenue for low-dose photodynamic therapy (PDT), which
has been proven to result in a selective uptake increase of anticancer drugs in tumor nodules in the
thoracic cavity [115]. Whether or not PIPAC offers benefits to administer more advanced formulations
for controlled IP drug delivery (e.g., in-situ cross-linkable hydrogels containing NPs loaded with
chemotherapeutic agents, Near Infrared (NIR)-triggered drug release from NPs for controlled IP drug
delivery, or low-dose PDT [65,116–118]) remains to be seen.
4. Conclusion and Future Directions
Over the past years, the utility of locoregional chemotherapy has attracted the attention of clinicians
to open the door to new approaches for the clinical management of PC, enabling them to address some
of the shortcomings typically associated with systemic palliative chemotherapy. Notably, local drug
delivery strategies could enhance the therapeutic responses to tumor eradication, by facilitating the
direct delivery of anti-neoplastic agents to the tumor site, thus mitigating the systemic adverse effects.
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Given the great promise shown by aerosolized drug delivery strategies for localized cancer therapy,
an innovative intra-abdominal aerosol chemotherapeutic approach, known as PIPAC, was recently
introduced to the IP therapy regimens. By benefiting from the physical properties of gas and pressure,
PIPAC may present new opportunities to the area of IP drug delivery compared to conventional liquid
IP chemotherapy, resulting in a more homogenous drug distribution pattern, together with deeper
drug penetration into tumor nodules within the peritoneal space. However, an issue that remains clear
is that PIPAC is still in its infancy and must mature enough to fulfill its potential in improving the
patient survival.
Furthermore, with the emergence of nanotechnology in the past few decades, a new wave of
utilizing nanomaterials has begun in IP cancer therapy, opening up several new possibilities in this field
ranging from an extended retention time and sustained drug release in the peritoneal cavity to targeted
drug delivery to peritoneal tumor nodules, among others. Although some of these opportunities
afforded by nanotechnology to the IP therapies may become realities in the foreseeable future, there is
still ample room to improve the development of clinically efficacious nanosystems for the treatment
of PC. The key to designing the next generation of nanotherapeutics for aerosol IP therapies heavily
involves a much deeper understanding of how nebulized nanoscale vehicles interact with the complex
biological environment of the peritoneal cavity and invoke biological responses which can in turn
determine the fate of nanoparticle-based drug delivery systems in vivo. Barriers to overcome include
drainage through the lymphatic system, phagocytosis by macrophages, and tumor accumulation and
penetration. Additionally, the combination with more advanced formulations for controlled drug
delivery could result in a more successful translation of aerosolized nanotherapeutics from a benchtop
to bedside, ensuring an enhanced quality of life for patients with PC. Nevertheless, we should keep
in mind that local drug delivery may not always be sufficient as a stand-alone approach, but can be
applied in combination with existing and emerging therapeutic strategies to offer a potential benefit
for enhancing the patient outcomes.
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